← Back to Search

Diagnostic Test

Low-Dose CT Scans for Testicular Cancer

N/A

Waitlist Available

Led By Peter Chung

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Phase A: Newly diagnosed testicular germ cell testicular cancer (GCT) with no clinical or tumour marker evidence of metastases

Phase A: ECOG performance status 0 or 1

Must not have

Any medical conditions that render the patient ineligible to undergo the protocol or procedure

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 9 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether low-dose CT scans are as effective as standard CT scans in detecting disease recurrence in patients with primary germ cell cancer of the testicles.

Who is the study for?

This trial is for individuals with Stage I testicular cancer who are in their first year of surveillance for non-seminoma or within the first two years for seminoma. They must have a good performance status, meaning they're fully active or restricted in physically strenuous activity but can do light work.

What is being tested?

The study is testing if low-dose computed tomography (LDCT) scans are as effective as standard CT scans at spotting cancer recurrence while reducing radiation exposure over up to ten years of patient follow-up.

What are the potential side effects?

While LDCT itself doesn't have side effects, repeated exposure to even low doses of radiation may slightly increase the risk of developing secondary cancers later on.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have newly diagnosed testicular cancer with no signs it has spread.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have any health issues that would prevent me from following the study's procedures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 9 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~9 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Difference in size of the retroperitoneal lymph node mass

Secondary study objectives

Amount of prospective documentation of treatment for testicular germ cell cancer relapse

Amount of prospective identification of first modality to detect relapse

Proportion of disease-free survival

+4 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Patients with testicular germ cell cancerExperimental Treatment1 Intervention

Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.

0 / 3Eligibility criteria met